Drug Development Gene Therapy Cancer Treatment Obesity Treatments Disease Mechanisms Drug Discovery Targeted Therapy RNA Therapeutics Antibiotic Resistance Small Molecule Drugs Microbial Therapies Pharmacology Molecular Therapies Disease Treatment Enzymes Molecular Pathways Inflammatory Diseases GLP-1 Therapy Signaling Pathways Gene Silencing Innovative Therapies Mast Cell Diseases Treatment Strategies Inflammation DNA Repair Protein-based Therapies Analgesics Antiviral Drug Development Diabetes Antibody Therapy Viral Therapies Polymer Therapy Protein Therapeutics Oral Therapies Phage Therapy Protein Targets Senotherapies Cancer Therapies Monoclonal Antibodies Transdermal Systems Drug Delivery Systems Weight Loss Medications Cell-Based Therapies Vitamin D Deficiency Bacterial Applications Regenerative Therapies Mitochondrial Disease Research Vaccines Anti-inflammatory Treatments Antibody Design Neuroscience
This points to Rab11B as a host target for blocking H3N2 entry, pending further validation before any therapeutic use.
